3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
11
Neoplasms
2
Neoplasm Metastasis
2
Bulbo-Spinal Atrophy, X-Linked
2
Prostatic Neoplasms, Castration-Resistant
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bites and Stings
1
Interventions
Specimen Handling
4
Biopsy
4
Whole-Body Irradiation
3
Mycophenolic Acid
3
Cyclosporine
3
Cyclophosphamide
3
fludarabine phosphate
2
decitabine and cedazuridine drug combination
2
Sirolimus
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Busulfan
2
venetoclax
1
tocilizumab
1
ruxolitinib
1
peginterferon alfa-2b
1
iadademstat
1
fludarabine
1
Tacrolimus
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Methotrexate
1
Idarubicin
1
Hyperbaric Oxygenation
1
Filgrastim
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Cord Blood Stem Cell Transplantation
1
Clofarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
abiraterone
×
30 days
×
Clear all
No trials found.